Teva's OTC revenue gets extra boost from Actavis

17 November 2016 - Deborah Wilkes

Archived

Acquiring Allergan's Actavis generics business, including the international OTC unit, helped lift Teva's OTC revenue by 40% as reported to US$356 million in the third quarter of 2016.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: